Skip to main content

Adolescent IGA Efficacy Results

In the treatment of adolescents (12-17 years) with uncontrolled moderate-to-severe atopic dermatitis

DUPIXENT demonstrated skin clearance

Significant skin clearance (primary endpoint; P<0.001)1,2,a

Efficacy results of DUPIXENT at Week 16 in AD‑1526b
DUPIXENT
(n=82)c 		PLACEBO
(n=85)
Achieved clear or almost‑clear skin
(IGA 0 or 1) 		24% 2%

aA clinical responder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2 points on a 0‑4 scale at Week 16 (primary efficacy outcome).1

bFull Analysis Set includes all subjects randomized.1

cAdolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.1

Visible results with DUPIXENT

In DUPIXENT clinical trials including adolescents, the primary endpoint was the proportion of subjects with an Investigator’s Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and a ≥2-point improvement at Week 16.1

Actual 12-year-old patient in the phase 3 adolescent DUPIXENT trial. Patient had a baseline IGA of 4 and EASI of 31. Individual results may vary.

Patient 1: Adolescent patient achieved a 2-point improvement in IGA

DRAG TO SEE
RESULTS

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline.1

  • This adolescent patient did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16

Explore more IGA
efficacy results

VIEW ADULT DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA VIEW CHILD (6 TO 11 YEARS) DATA VIEW AD WITH HAND AND/OR FOOT INVOLVEMENT DATA
(AGES 12+ YEARS)

READY TO PRESCRIBE DUPIXENT?

DOSAGE AND ADMINISTRATION